Etzer Darout

Barclays | Healthcare

Etzer Darout is an analyst from Barclays specializing in the Healthcare sector. Ranked #1431 out of 4678 analysts, they have issued 102 stock ratings with a success rate of 90.00% and an average return of 13.93%.

Etzer Darout has a well-established track record, with 102 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 90.00% and an average return of 13.93%, underscoring their expertise and ability to identify winning opportunities for investors.

#1431

Out of 4678

102

Total Ratings

+90.00%

Success Rate

+13.93%

Average Return

Recent Ratings Analysis

NUVL

Jun 10, 2026

Target

$124.00

Current

$123.35

Performance

0.00%

Etzer Darout rated NUVL as Equal-Weight on Jun 10, 2026, setting a price target of 124. The Hold stance appears justified, as shares hovered around 123.35 with a 0.00% move.

JAZZ

May 27, 2026

Target

$253.00

Current

$229.63

Performance

-3.34%

On May 27, 2026, JAZZ was given a Overweight rating by Etzer Darout, with a target price of 253. The stock traded sideways with a -3.34% move, keeping the bullish thesis unresolved.

RLAY

May 20, 2026

Target

$27.00

Current

$13.49

Performance

3.61%

RLAY received a Overweight rating from Etzer Darout on May 20, 2026, aiming for 27. Price action was muted, as shares hovered around 13.49 despite the bullish outlook.

ARVN

May 13, 2026

Target

$20.00

Current

$6.98

Performance

-29.28%

On May 13, 2026, Etzer Darout published a Overweight outlook on ARVN, with a target of 20. Market action contradicted the Buy thesis, as shares slipped to 6.98.

ANAB

May 13, 2026

Target

$75.00

Current

$52.10

Performance

-16.89%

Etzer Darout on May 13, 2026 assigned ANAB a Overweight rating, with a price target of 75. The call has struggled to gain traction, with shares losing 16.89%.

CLDX

May 08, 2026

Target

$48.00

Current

$29.35

Performance

-13.60%

On May 08, 2026, Etzer Darout reaffirmed CLDX with a Overweight rating, targeting 48. Shares slid 13.60% despite the recommendation, highlighting downside risks.

SRRK

May 08, 2026

Target

$55.00

Current

$44.09

Performance

-8.89%

SRRK was rated Overweight by Etzer Darout on May 08, 2026, with a price objective of 55. This case shows how bullish projections can fail, with the stock now below 44.09.

SNDX

May 01, 2026

Target

$37.00

Current

$17.58

Performance

—

On May 01, 2026, Etzer Darout initiated coverage on SNDX with a Overweight rating and target of 37. Neutral price movement of % leaves room for interpretation.

ORKA

Apr 28, 2026

Target

$160.00

Current

$64.03

Performance

-13.46%

Etzer Darout issued a Overweight recommendation for ORKA on Apr 28, 2026, price target set at 160. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

TVRD

Apr 20, 2026

Target

$3.00

Current

$2.70

Performance

-16.15%

On Apr 20, 2026, TVRD was evaluated by Etzer Darout, who gave a Underweight rating and target of 3. The recommendation was proven wrong by upward action toward 3.

MGNX

Apr 20, 2026

Target

$6.00

Current

$3.87

Performance

11.21%

Etzer Darout rated MGNX as Overweight on Apr 20, 2026, setting a price target of 6. The call has proven timely, with shares rising 11.21% toward the price target of 6.

EXEL

Apr 20, 2026

Target

$45.00

Current

$52.58

Performance

20.57%

On Apr 20, 2026, EXEL was given a Equal-Weight rating by Etzer Darout, with a target price of 45. The stock rallied from 52.58 to 52.58 after the Hold rating, surprising to the upside.

JANX

Apr 20, 2026

Target

$14.00

Current

$13.15

Performance

-17.14%

JANX received a Underweight rating from Etzer Darout on Apr 20, 2026, aiming for 14. Investors who stayed short missed an upside surprise of -17.14%.

TERN

Mar 30, 2026

Target

$53.00

Current

$52.95

Performance

0.13%

On Mar 30, 2026, Etzer Darout published a Equal-Weight outlook on TERN, with a target of 53. Sideways action left the Hold view intact, with no major move since 52.95.

ABVX

Mar 24, 2026

Target

$148.00

Current

$98.03

Performance

-11.02%

Etzer Darout on Mar 24, 2026 assigned ABVX a Overweight rating, with a price target of 148. The call has struggled to gain traction, with shares losing 11.02%.

PTGX

Mar 19, 2026

Target

$119.00

Current

$105.77

Performance

4.02%

On Mar 19, 2026, Etzer Darout reaffirmed PTGX with a Overweight rating, targeting 119. Market indecision has kept the 119 target in a holding pattern.

CTMX

Mar 19, 2026

Target

$16.00

Current

$2.91

Performance

-39.12%

CTMX was rated Overweight by Etzer Darout on Mar 19, 2026, with a price objective of 16. This case shows how bullish projections can fail, with the stock now below 2.91.

BNTX

Mar 11, 2026

Target

$143.00

Current

$86.15

Performance

-5.16%

On Mar 11, 2026, Etzer Darout initiated coverage on BNTX with a Outperform rating and target of 143. The Buy call has yet to be validated as shares remain 56.85 away from the target.

CCCC

Feb 27, 2026

Target

$7.00

Current

$3.87

Performance

43.33%

Etzer Darout issued a Overweight recommendation for CCCC on Feb 27, 2026, price target set at 7. Investors following the Buy call captured upside momentum, with shares now at 3.87.

XNCR

Feb 26, 2026

Target

$27.00

Current

$11.83

Performance

-12.69%

On Feb 26, 2026, XNCR was evaluated by Etzer Darout, who gave a Overweight rating and target of 27. Investors saw limited payoff as shares fell short of the 27 target.

VIR

Feb 25, 2026

Target

$30.00

Current

$8.25

Performance

-17.50%

Etzer Darout rated VIR as Overweight on Feb 25, 2026, setting a price target of 30. The stock has underperformed, dropping 17.50% despite the bullish target of 30.

IOVA

Feb 25, 2026

Target

$11.00

Current

$3.78

Performance

-1.31%

On Feb 25, 2026, IOVA was given a Overweight rating by Etzer Darout, with a target price of 11. The stock traded sideways with a -1.31% move, keeping the bullish thesis unresolved.

INCY

Feb 18, 2026

Target

$117.00

Current

$105.39

Performance

2.33%

INCY received a Overweight rating from Etzer Darout on Feb 18, 2026, aiming for 117. Price action was muted, as shares hovered around 105.39 despite the bullish outlook.

KYMR

Jan 28, 2026

Target

$133.00

Current

$78.23

Performance

9.94%

On Jan 28, 2026, Etzer Darout published a Overweight outlook on KYMR, with a target of 133. Shares gained 9.94%, underscoring the accuracy of the bullish outlook toward 133.

CRVS

Jan 21, 2026

Target

$28.00

Current

$11.16

Performance

-49.62%

Etzer Darout on Jan 21, 2026 assigned CRVS a Overweight rating, with a price target of 28. The call has struggled to gain traction, with shares losing 49.62%.

RAPT

Jan 21, 2026

Target

$58.00

Current

$58.01

Performance

0.69%

On Jan 21, 2026, Etzer Darout reaffirmed RAPT with a Equal-Weight rating, targeting 58. The neutral call matched muted market action of 0.69%.

SMMT

Dec 17, 2025

Target

$18.00

Current

$13.05

Performance

-23.28%

SMMT was rated Equal-Weight by Etzer Darout on Dec 17, 2025, with a price objective of 18. Investors who stayed cautious avoided some of the 23.28% decline.

KURA

Nov 24, 2025

Target

$28.00

Current

$8.68

Performance

-26.00%

On Nov 24, 2025, Etzer Darout initiated coverage on KURA with a Overweight rating and target of 28. The Buy call has yet to be validated as shares remain 19.32 away from the target.

MNPR

Oct 13, 2025

Target

$125.00

Current

$59.42

Performance

-41.77%

Etzer Darout issued a Overweight recommendation for MNPR on Oct 13, 2025, price target set at 125. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

MRUS

Sep 30, 2025

Target

$97.00

Current

$90.00

Performance

-4.41%

On Sep 30, 2025, MRUS was evaluated by Etzer Darout, who gave a Equal-Weight rating and target of 97. Hold sentiment was validated by subdued trading with no breakout beyond 90.

IVA

Sep 02, 2025

Target

$13.00

Current

$3.78

Performance

-28.14%

Etzer Darout rated IVA as Buy on Sep 02, 2025, setting a price target of 13. The stock has underperformed, dropping 28.14% despite the bullish target of 13.

QTTB

Feb 11, 2025

Target

$3.00

Current

$12.87

Performance

346.87%

On Feb 11, 2025, QTTB was given a Market Perform rating by Etzer Darout, with a target price of 3. The stock rallied from 12.87 to 12.87 after the Hold rating, surprising to the upside.

IGMS

Jan 10, 2025

Target

$2.00

Current

$1.27

Performance

-39.23%

IGMS received a Market Perform rating from Etzer Darout on Jan 10, 2025, aiming for 2. The Hold stance proved prudent, with the market softening by 39.23%.

JSPR

Dec 06, 2024

Target

$63.00

Current

$0.46

Performance

-97.93%

On Dec 06, 2024, Etzer Darout published a Outperform outlook on JSPR, with a target of 63. Market action contradicted the Buy thesis, as shares slipped to 0.4643.

TRML

Dec 06, 2024

Target

$50.00

Current

$47.98

Performance

85.04%

Etzer Darout on Dec 06, 2024 assigned TRML a Outperform rating, with a price target of 50. The Buy call aligned well with market performance, producing a gain of 85.04%.

NRIX

Dec 06, 2024

Target

$35.00

Current

$15.30

Performance

-28.40%

On Dec 06, 2024, Etzer Darout reaffirmed NRIX with a Outperform rating, targeting 35. Shares slid 28.40% despite the recommendation, highlighting downside risks.

ACRV

Sep 16, 2024

Target

$28.00

Current

$1.38

Performance

-83.23%

ACRV was rated Outperform by Etzer Darout on Sep 16, 2024, with a price objective of 28. This case shows how bullish projections can fail, with the stock now below 1.38.

FATE

May 10, 2024

Target

$6.00

Current

$1.87

Performance

-54.17%

On May 10, 2024, Etzer Darout initiated coverage on FATE with a Market Perform rating and target of 6. The rating matched the stock’s inability to hold above 1.87.

AZN

Apr 26, 2024

Target

$82.00

Current

$178.96

Performance

138.07%

Etzer Darout issued a Outperform recommendation for AZN on Apr 26, 2024, price target set at 82. Investors following the Buy call captured upside momentum, with shares now at 178.96.

NVS

Feb 23, 2024

Target

$114.00

Current

$148.12

Performance

42.56%

On Feb 23, 2024, NVS was evaluated by Etzer Darout, who gave a Market Perform rating and target of 114. Investors who stayed in despite the Hold saw upside of 42.56%.

Frequency Asked Questions

Who is Etzer Darout?

Etzer Darout is an analyst from Barclays specializing in the Healthcare sector.

What is Etzer Darout's success rate?

Etzer Darout currently has a success rate of +90.00%.

How many ratings has Etzer Darout issued?

Etzer Darout has issued 102 stock ratings so far.

What is the average return of Etzer Darout's calls?

Their stock ratings have generated an average return of +13.93%.

What is Etzer Darout's ranking?

Etzer Darout is ranked #1431 out of 4678 analysts.

What types of ratings does Etzer Darout give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Etzer Darout?

You can follow Etzer Darout by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Etzer Darout?

Their latest rating was a Hold on NUVL issued on 2026-06-10.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep